Spare.

A61K

(21) Int. Application Number: PCT/EP96/00681

(22) Int. Filing Date: 15 February 1996 (15.02.96)

(30) Priority Data:
9503863.4 25 February 1995 (25.02.95) GB

(71) Applicant *(for all designated States except US)*: SMITHKLINE BEECHAM BIOLOGICALS S.A. [BE/BE]; Rue de l'Institut 89, B-1330 Rixensart (BE).

(72) Inventors; and
(75) Inventors/Applicants *(for US only)*: HAUSER, Pierre [BE/BE]; (BE). GARCON, Nathalie, Marie-Josephe, Claude [FR/BE]; (BE). DESMONS, Pierre [BE/BE]; SmithKline Beecham Biologicals S.A., Rue de l'Institut 89, B-1330 Rixensart (BE).

(74) Agent: DALTON, Marcus, Jonathan, William; SmithKline Beecham, Corporate Intellectual Property, SB House, Great West Road, Brentford, Middlesex TW8 9BD (GB).

(81) Designated States: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AZ, BY, KG, KZ, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).

Published
With international search report.
Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

(51) International Patent Classification 6: A61K 39/39 // 39/29, 39/12, 31/715

A1

(11) Int. Publication Number: WO 96/26741

(43) Int. Publication Date: 6 September 1996 (06.09.96)

(54) Title: HEPATITIS B VACCINE

(57) Abstract

A novel vaccine formulation is provided, compromising a hepatitis B component, particularly hepatitis B surface antigen, in combination with aluminum phosphate and 3 de-O-acylated monophosphoryl lipid A.

(21) Int. Application Number: PCT/US96/02631

(22) Int. Filing Date: 27 February 1996 (27.02.96)

(30) Priority Data:
08/396,207 28 February 1995 (28.02.95) US
08/485,472 7 June 1995 (07.06.95) US

(60) Parent Applications or Grants
(63) Related by Continuation
US 08/396,207 (CIP)
Filed on 28 February 1995 (28.02.95)
US 08/485,472 (CIP)
Filed on 7 June 1995 (07.06.95)

(71) Applicant *(for all designated States except US)*: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA [US/US]; 22nd floor, 300 Lakeside Drive, Oakland, CA 94612-3550 (US).

(72) Inventors; and
(75) Inventors/Applicants *(for US only)*: HAMMOND, H., Kirk [US/US]; 5770 Waverly Avenue, La Jolla, CA 92037 (US). GIORDANO, Frank, J. [US/US]; 13119 Caminito Mar Villa, Del Mar, CA 92014 (US). DILLMAN, Wolfgang, H. [US/US]; 355 S. Nardo Avenue, Solana Beach, CA 92075 (US).

(74) Agent: BERLINER, Robert; Robbins, Berliner & Carson, 5th floor, 201 N. Figueroa Street, Los Angeles, CA 90012-2628 (US).

(51) International Patent Classification 6: A61K 48/00, C12N 15/00

A1

(11) Int. Publication Number: WO 96/26742

(43) Int. Publication Date: 6 September 1996 (06.09.96)

(54) Title: GENE TRANSFER-MEDIATED ANGIOGENESIS THERAPY

(57) Abstract

The transgene-inserted replication-deficit adenovirus vector is effectively used in *in vivo* gene therapy for peripheral vascular disease and heart disease, including myocardial ischemia, by a single intra-femoral artery or intracoronary injection directly conducted deeply in the lumen of the one or both femoral or coronary arteries (or graft vessels) in an amount sufficient for transfecting cells in a desired region.